Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer

Published:2021-10 Issue:10 Volume:33 Page:619-626
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Lim J.U.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference58 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Cancer treatment and survivorship statistics, 2016;Miller;CA Cancer J Clin,2016

3. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

4. Incidence and characteristics of epidermal growth factor receptor (EGFR) mutation in non-small-cell lung cancer (adenocarcinoma histology): a report of 106 patients from Kolkata;Chatterjee;Indian J Cancer,2017

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

2. Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer;Thoracic Cancer;2024-05-27

3. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

4. The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC;iScience;2023-07

5. Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs;Bioorganic Chemistry;2022-11